Publication:
miRNAs in glomerular diseases: from pathogenic insight to therapeutic potential: a narrative review

dc.contributor.coauthorApetrii, Mugurel
dc.contributor.coauthorCostache, Alexandru Dan
dc.contributor.coauthorCostache Enache, Irina Iuliana
dc.contributor.coauthorVoroneanu, Luminita
dc.contributor.coauthorCovic, Andreea Simona
dc.contributor.coauthorScripcariu, Dragos Viorel
dc.contributor.coauthorCovic, Adrian
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2026-02-26T07:12:19Z
dc.date.available2026-02-25
dc.date.issued2026
dc.description.abstractThis article explores the multifaceted role of micro-ribonucleic acids (RNAs) (miRNAs) as critical posttranscriptional regulators in renal physiology and disease, with a focus on their emerging significance in glomerulopathies. miRNAs, small endogenous noncoding RNAs, modulate gene expression by promoting messenger RNA degradation or inhibiting translation, thereby orchestrating essential cellular processes such as proliferation, differentiation, apoptosis, and stress responses. Recent advances have revealed that aberrant miRNA expression profiles are intricately linked to the pathogenesis and progression of various renal diseases, including acute kidney injury, chronic kidney disease, alloimmune injury in solid organ transplantation and glomerulonephritis. This review summarizes the pathogenic and protective roles of miRNAs in major glomerulopathies, discusses their potential as diagnostic and prognostic biomarkers, and outlines future directions for their integration into personalized therapeutic strategies. At the moment, it is not fully established whether some of these mechanisms are the primary pathogenic driver or a secondary response. Combining miRNAs with other molecular markers may further enhance diagnostic and predictive accuracy, facilitating clinical translation, while selective targeting of specific miRNAs at different stages of disease progression could offer promising therapeutic opportunities.
dc.description.fulltextYes
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessGold OA
dc.description.openaccessGreen OA
dc.description.peerreviewstatusN/A
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.versionN/A
dc.identifier.doi10.3390/cells15020094
dc.identifier.eissn2073-4409
dc.identifier.embargoNo
dc.identifier.issue2
dc.identifier.pubmed41597170
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-105028840362
dc.identifier.urihttps://doi.org/10.3390/cells15020094
dc.identifier.urihttps://hdl.handle.net/20.500.14288/32454
dc.identifier.volume15
dc.identifier.wos001670169600001
dc.keywordsmicroRNA
dc.keywordsGlomerulopathies
dc.keywordsLupus nephritis
dc.keywordsDiabetic nephropathy
dc.language.isoeng
dc.publisherMDPI
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofCells
dc.relation.openaccessYes
dc.rightsCC BY-NC-ND (Attribution-NonCommercial-NoDerivs)
dc.rights.uriAttribution, Non-commercial, No Derivative Works (CC-BY-NC-ND)
dc.subjectCell biology
dc.titlemiRNAs in glomerular diseases: from pathogenic insight to therapeutic potential: a narrative review
dc.typeReview
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files